Global Blood Therapeutics shares jumped on Tuesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Oxbryta (voxelotor) tablets for the...
ACLS raised to Equal Weitght at Lehman.AEG cut to Peer Perform at Bear Stearns.ALXN cut to Neutral at Credit Suisse.CSC raised to Hold at Jefferies.CSCO raised to Outperform at Bear Stearns.DKS cut...
Here, 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
Here 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
Insmed has filed with the SEC for a secondary offering. This follows a surge in the share price following positive late-stage results from its clinical study in the treatment of nontuberculous...
One relatively small clinical-stage biopharmaceutical player called Global Blood Therapeutics may be about to change how sickle cell disease treatment goes.
Gensight Biologics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
A 24/7 Tempo analysis reveals the smallest NFL player of the Super Bowl era.
Genfit SA (NASDAQ: GNFT) shot up on Monday after the company announced an agreement with Lab Corporation of America Holdings (NYSE: LH). This agreement is ultimately for Genfit’s technology to...
Global Blood Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering.
A biopharmaceutical company working on developing and commercializing treatments for serious blood-based disorders priced its initial public offering (IPO) above the expected range Tuesday.
Source: ThinkstockGlobal Blood Therapeutics Inc. filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The expected price range is...
Shares of Global Blood Therapeutics saw a handy gain going into the weekend following positive results from its mid-stage clinical trial.
The IPO calendar for this week includes just one potential public offering, and that for a company that has twice delayed its planned debut.
Two firms launched initial public offerings (IPOs) last week, and neither was able to match its hopes with the reality of the market.